Pharmacologic Prevention of Recurrent Vasovagal Syncope: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials Publisher Pubmed



Behnoush AH^{1, 2, 3, 4} ; Yazdani K⁵ ; Khalaji A^{1, 2, 3} ; Tavolinejad H^{1, 2} ; Aminorroaya A^{1, 2} ; Jalali A¹ ; Tajdini M¹ Show Affiliations
Source: Heart Rhythm Published:2023

Abstract

Vasovagal syncope (VVS) is a transient loss of consciousness that currently imposes a high burden on health care systems with limited evidence of the comparative efficacy of available pharmacologic interventions. This study aims to compare all pharmacologic therapies suggested in randomized controlled trials (RCTs) through systematic review and network meta-analysis. A systematic search in PubMed, Embase, Web of Science, and Cochrane Library was conducted to identify RCTs evaluating pharmacologic therapies for patients with VVS. The primary outcome was spontaneous VVS recurrence. The secondary outcome was a positive head-up tilt test (HUTT) after receiving intervention, regarded as a lower level of evidence. Pooled risk ratio (RR) with 95% confidence interval (CI) was calculated using random-effect network meta-analysis. Pairwise meta-analysis for comparison with placebo was also performed when applicable. The surface under the cumulative ranking curve analysis was conducted to rank the treatments for each outcome. Twenty-eight studies with 1744 patients allocated to different medications or placebo were included. Network meta-analysis of the reduction in the primary outcome showed efficacy for midodrine (RR 0.55; 95% CI 0.35–0.85) and fluoxetine (especially in patients with concomitant anxiety) (RR 0.36; 95% CI 0.16–0.84). In addition, midodrine and atomoxetine were superior to other treatment options, considering positive HUTT (RR 0.37; 95% CI 0.23–0.59; and RR 0.49; 95% CI 0.28–0.86, respectively). Overall, midodrine was the only agent shown to reduce spontaneous syncopal events. Fluoxetine also seems to be beneficial but should be studied further in RCTs. Our network meta-analysis did not find evidence of the efficacy of any other medication. © 2022 Heart Rhythm Society